Federal Register Notice: FDA’s Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet 11/2, from 8 a.m. to 3:30 p.m. at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The subcommittee will consider and discuss regulatory, academic, and industry perspectives for developing anticoagulant products in children. Issues for discussion will include identifying strategies to encourage and facilitate studies of anticoagulants in children that will result in informative pediatric labeling, appropriate endpoints for studies of anticoagulants in pediatric patients, and the role of pharmacokinetic/pharmacodynamic studies to support a pediatric indication for anticoagulants. Contact Caleb Briggs, (301) 796-9001. To view this notice, click here.